This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LumiraDx Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Veronique Ameye

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	9.7yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	8.8yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower

Dec 20

LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors

Apr 17

What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today

Nov 16

Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022

Aug 20

LumiraDx GAAP EPS of -$0.58, revenue of $44.7M

Aug 18

Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx

Jul 15

CEO

Veronique Ameye (48 yo)

9.7yrs

Tenure

Ms. Veronique Ameye, Esq. EMBA, is CEO & General Counsel of LumiraDx AS. Ms. Ameye has been General Counsel at LumiraDx Limited since February 2015, serves as its Chief Executive Officer since November 01,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Veronique Ameye	CEO & General Counsel	9.7yrs	geen gegevens	geen gegevens
Dorian LeBlanc	CFO & VP of Global Operations	7.9yrs	geen gegevens	geen gegevens
Colleen McMillen	Vice President of Communications	no data	geen gegevens	geen gegevens
Andy Ward	National Sales Director - UK	no data	geen gegevens	geen gegevens
David Walton	Chief Commercial Officer	10.2yrs	geen gegevens	geen gegevens
Giffin Daughtridge	President of North America Commercial Operations & Global Molecular Solutions	1.2yrs	geen gegevens	geen gegevens
Melissa Garcia	VP & Corporate Counsel	no data	geen gegevens	geen gegevens

8.8yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LMDX.F is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Troyen Brennan	Non-Employee Director	7.9yrs	geen gegevens	geen gegevens
Bruce Keogh	Independent Non-Employee Director	6.8yrs	geen gegevens	geen gegevens
George Neble	Independent Co-Chairman of the Board	4.3yrs	geen gegevens	geen gegevens
Donald Berwick	Independent Non-Employee Director	6.8yrs	geen gegevens	geen gegevens
Lurene Julia Joseph	Independent Co-Chairman of the Board	7.9yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LMDX.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

This company listing is no longer active

LumiraDx Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer

LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors

LumiraDx Limited Announces Executive Changes

Insufficient new directors

LumiraDx Limited, Annual General Meeting, Dec 15, 2022

Recent updates

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

Nasdaq to Delist Common Stock of LumiraDx Limited

LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index

LumiraDx Announces Its Securities To Be Suspended from Trading on Nasdaq At the Open of Business on January 9, 2024

Nasdaq to Suspend Trading of LumiraDx's Securities and to File Form 25-NSE with SEC

Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower

LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer

LumiraDx Announces Receipt of Nasdaq Delisting Determination, Plans to Appeal

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited Announces Executive Changes

LumiraDx Limited to Report Q2, 2023 Results on Aug 24, 2023

Insufficient new directors

LumiraDx Limited to Report Q1, 2023 Results on May 16, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors

Price target decreased by 12% to US$1.83

Consensus revenue estimates decrease by 51%, EPS upgraded

Price target decreased by 29% to US$2.49

Full year 2022 earnings: EPS and revenues miss analyst expectations

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

Lumiradx Receives FDA Emergency Use Authorization and UK CTDA Approval for Its Fast Lab Solutions Multiplex Covid and Influenza Molecular Assay

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LumiraDx Limited Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today

LumiraDx Limited, Annual General Meeting, Dec 15, 2022

Price target decreased to US$4.31

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Third quarter 2022 earnings: Revenues exceed analyst expectations

LumiraDx Limited to Report Q3, 2022 Results on Nov 09, 2022

LumiraDx Partners with British in Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Consensus EPS estimates fall by 25%

Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022

Price target decreased to US$6.38

Second quarter 2022 earnings: Revenues miss analyst expectations

LumiraDx GAAP EPS of -$0.58, revenue of $44.7M

LumiraDx Limited to Report Q2, 2022 Results on Aug 18, 2022

Investor sentiment deteriorated over the past week

LumiraDx Limited has completed a Follow-on Equity Offering in the amount of $75.25 million.

Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx

Investor sentiment deteriorated over the past week

Price target decreased to US$7.63

Price target decreased to US$8.00

Investor sentiment deteriorated over the past week

LumiraDx Limited Expands Its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

LumiraDx Limited Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

Consensus EPS estimates fall by 72%

Price target decreased to US$9.75

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LumiraDx Limited to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.56

Consensus EPS estimates fall by 75%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

LumiraDx Limited to Report Q4, 2021 Results on Mar 10, 2022

LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete

Consensus EPS estimates increase by 96%

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LumiraDx Limited Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions

Third quarter 2021 earnings released: EPS US$0.63 (vs US$0.82 loss in 3Q 2020)

CEO

Tenure

Leiderschapsteam

Gemiddelde duur